Volume 188, Issue 4, Pages (October 2012)

Slides:

Advertisements

Similar presentations

Functional Analysis of the Neurofibromatosis Type 2 Protein by Means of Disease- Causing Point Mutations Renee P. Stokowski, David R. Cox The American.

Advertisements

Genetic testing for high-risk colon cancer patients1 William M. Grady Gastroenterology Volume 124, Issue 6, Pages (May 2003) DOI: /S (03)

Volume 189, Issue 4, Pages (April 2013)

Volume 187, Issue 6, Pages (June 2012)

Jeffrey Marotte, Wilson Alobuia, Rochelle Frazier

592 PATIENT COMPLIANCE AND OUTCOMES IN BOWEL AND BLADDER DYSFUNCTION TREATED WITH PELVIC FLOOR PHYSICAL THERAPY Zachary Liss, Bryan Roelof, Theodore.

Volume 155, Issue 3, Pages (March 1996)

Volume 164, Issue 6, Pages (December 2000)

MP60-03 PROSTATE CANCER IN THE ELDERLY

Hematocrit Response and Risk Factors for Significant Hematocrit Elevation with Implantable Testosterone Pellets Russell P. Hayden, Nelson E. Bennett,

Prostate Cancer Biomarker Profiles in Urinary Sediments and Exosomes

Volume 195, Issue 4, Pages e13-e14 (April 2016)

MP25-20 A PERI-PROCEDURAL POVIDONE IODINE RECTAL PREPARATION DECREASES BACTERIURIA AND BACTEREMIA FOLLOWING PROSTATE NEEDLE BIOPSY Jay D. Raman, Kathleen.

Evaluation and Treatment of Lower Urinary Tract Symptoms in Older Men

Benjamin Herrick, Cameron Banga, Michael Phelps, Ronald Yap

Volume 195, Issue 5, Pages (May 2016)

Volume 180, Issue 5, Pages (November 2008)

Volume 191, Issue 3, Pages (March 2014)

2327 PROSTATE CANCER STAGE, GRADE AND POSITIVE MARGIN RATE IN MEN WITH PSA ≥ 1 ng/ml UNDERGOING RADICAL PROSTATECTOMY: POPULATION DATA ANALYSIS Sergey.

Prostate Cancer Predictive Simulation Modelling, Assessing the Risk Technique (PCP- SMART): Introduction and Initial Clinical Efficacy Evaluation Data.

The Male Factor in Fertility and Infertility. II

Volume 4, Issue 5, Pages (September 2017)

Volume 187, Issue 4, Pages e188-e189 (April 2012)

Volume 191, Issue 6, Pages (June 2014)

Primary Small Cell Carcinoma Arising from a Bladder Diverticulum

Volume 199, Issue 1, Pages (January 2018)

What Impacts the All Cause Risk of Reoperation after Pelvic Organ Prolapse Repair? A Comparison of Mesh and Native Tissue Approaches in 110,329 Women

Bladder Lymphoma The Journal of Urology

Volume 191, Issue 1, Pages (January 2014)

Volume 199, Issue 4, Pages e143-e144 (April 2018)

Cystic Nephroma of the Kidney

Volume 199, Issue 1, (January 2018)

Seminal Vesicle Invasion by Adenocarcinoma of the Prostate

Yolk Sac Tumor of the Testis

Volume 199, Issue 6, Pages (June 2018)

Oncocytoma of the Kidney

Mark H. Ebell, Taylor Radke, Jack Gardner The Journal of Urology

Paratesticular Serous Papillary Borderline Tumor

Volume 183, Issue 3, Pages (March 2010)

Volume 189, Issue 1, Pages (January 2013)

Combined Ciprofloxacin and Amikacin Prophylaxis in the Prevention of Septicemia After Transrectal Ultrasound Guided Biopsy of the Prostate Elijah O.

Regional Variation in Quality of Prostate Cancer Care

Volume 189, Issue 1, Pages S45-S50 (January 2013)

Volume 197, Issue 2, Pages S189-S197 (February 2017)

MP57-17 CAN PROSTATIC SPECIFIC ANTIGEN VELOCITY (PSAV) IMPROVE THE DIAGNOSTIC ACCURACY OF PROSTATE IMAGING REPORTING AND DATA SYSTEM (PI-RADS) SCORE.

Volume 199, Issue 1, Pages (January 2018)

Pseudohyperplastic Adenocarcinoma of the Prostate

Towards Early and More Specific Diagnosis of Prostate Cancer

Ongoing Gleason Grade Migration in Localized Prostate Cancer and Implications for Use of Active Surveillance Adam B. Weiner, Ruth Etzioni, Scott E. Eggener

Volume 184, Issue 4, Pages (October 2010)

Volume 185, Issue 6, Pages (June 2011)

Volume 182, Issue 6, Pages (December 2009)

Volume 197, Issue 4, Pages e335-e336 (April 2017)

Volume 185, Issue 2, Pages (February 2011)

Volume 199, Issue 1, Pages (January 2018)

Luis Martínez-Piñeiro European Urology Supplements

Volume 58, Issue 1, Pages (July 2010)

Volume 50, Issue 5, Pages (November 2006)

CHEK2*1100delC and Susceptibility to Breast Cancer: A Collaborative Analysis Involving 10,860 Breast Cancer Cases and 9,065 Controls from 10 Studies

Staging of pelvic lymph nodes in patients with prostate cancer: Usefulness of multiple b value SE-EPI diffusion-weighted imaging on a 3.0T MR system

Evaluation of the HAS-BLED, ATRIA, and ORBIT Bleeding Risk Scores in Patients with Atrial Fibrillation Taking Warfarin Keitaro Senoo, MD, Marco Proietti,

The Molecular Pathology of Primary Immunodeficiencies

GeneTests: Integrating Genetic Services into Patient Care*

Thomas Steuber, Matthew Frank O'Brien, Hans Lilja European Urology

Volume 54, Issue 5, Pages (November 2008)

Erratum The American Journal of Human Genetics

The Reply The American Journal of Medicine

Physical Function in Patients with Cancer

Alice S. Whittemore, Jerry Halpern

Genomewide Comparison of DNA Sequences between Humans and Chimpanzees

Presentation transcript:

Volume 188, Issue 4, Pages 1124-1130 (October 2012) Effectiveness of the Combined Evaluation of KLK3 Genetics and Free-to-Total Prostate Specific Antigen Ratio for Prostate Cancer Diagnosis Carlo-Federico Zambon, Tommaso Prayer-Galetti, Daniela Basso, Andrea Padoan, Elisa Rossi, Silvia Secco, Michela Pelloso, Paola Fogar, Filippo Navaglia, Stefania Moz, Filiberto Zattoni, Mario Plebani The Journal of Urology Volume 188, Issue 4, Pages 1124-1130 (October 2012) DOI: 10.1016/j.juro.2012.06.030 Copyright © 2012 American Urological Association Education and Research, Inc. Terms and Conditions

Figure 1 tPSA, f/tPSA and Gleason score in patients without PCa (Ref.) and those with PCa after subdivision by 3 Gleason score classes, including 6 or less, 7 and greater than 7. Columns indicate mean. Bars indicate SE. Asterisk indicates Bonferroni test for pairwise comparison p <0.0001 vs reference group. The Journal of Urology 2012 188, 1124-1130DOI: (10.1016/j.juro.2012.06.030) Copyright © 2012 American Urological Association Education and Research, Inc. Terms and Conditions

Figure 2 ROC curve analysis of f/tPSA in patients with different KLK3 genetics (groups 1 to 4). ROC AUC was 0.84 (95% CI 0.74–0.94) for group 1, 0.71 (95% CI 0.66–0.75) for group 2, 0.67 (95% CI 0.60–0.74) for group 3 and 0.75 (95% CI 0.68–0.82) for group 4. The Journal of Urology 2012 188, 1124-1130DOI: (10.1016/j.juro.2012.06.030) Copyright © 2012 American Urological Association Education and Research, Inc. Terms and Conditions